| Identification | Back Directory | [Name]
Ethyl (2Z)-chloro[(4-methoxyphenyl)hydrazono]ethanoate | [CAS]
473927-63-8 | [Synonyms]
Apixaban I
Apixaban int
Apixaban Impurity O
Ethyl (2Z)-chloro[(4-methoxyphenyl)hydrazono]acetate
Ethyl (2Z)-chloro[(4-methoxyphenyl)hydrazono]ethanoate
Acetic acid, chloro[(4-Methoxyphenyl)hydrazono]-, ethyl ester, (2Z)-
ethyl (2Z)-2-chloro-2-[2-(4-methoxyphenyl)hydrazin-1-ylidene]acetate
(2Z)-2-Chloro-2-[2-(4-methoxyphenyl)hydrazinylidene]acetic acid ethyl ester
Acetic acid, 2-chloro-2-[2-(4-methoxyphenyl)hydrazinylidene]-, ethyl ester, (2Z)- | [EINECS(EC#)]
696-101-8 | [Molecular Formula]
C11H13ClN2O3 | [MOL File]
473927-63-8.mol | [Molecular Weight]
256.69 |
| Chemical Properties | Back Directory | [Boiling point ]
349.0±44.0 °C(Predicted) | [density ]
1.23 | [vapor pressure ]
0.008Pa at 25℃ | [pka]
11.63±0.10(Predicted) | [InChI]
InChI=1S/C11H13ClN2O3/c1-3-17-11(15)10(12)14-13-8-4-6-9(16-2)7-5-8/h4-7,13H,3H2,1-2H3/b14-10- | [InChIKey]
ATNPZEGMKLGIFA-UVTDQMKNSA-N | [SMILES]
C(OCC)(=O)/C(/Cl)=N/NC1=CC=C(OC)C=C1 | [LogP]
2.53 |
| Hazard Information | Back Directory | [Uses]
Ethyl (2Z)-chloro[(4-methoxyphenyl)hydrazono]ethanoate can be used as organic synthesis intermediates and pharmaceutical intermediates, mainly used in laboratory research and development and chemical and pharmaceutical production processes. | [Synthesis]
Preparation of ethyl (2Z)-chloro[(4-methoxyphenyl)hydrazono]ethanoate To p-anisidine (16 g, 0.129 mol) in conc. HCL (40 mL), 100 mL) H2O, cooled to -5?? C. and sodium nitrite (9.4 g, 0.136 mol) in H2O (60 mL) was added. The reaction mixture was stirred at -5?? C. for 20 min and a mixture of ethylchloroacetoacetate (22 g, 0.133 mol), ethanol (100 mL), sodiumacetate (32 g, 0.389 mmol), and H2O (400 mL) was added. The reaction was allowed to warm up to room temperature and stirred for 2h. The product precipitated as a black solid. It was filtered and dried (30 g). 1H-NMR (CDCl3) |? 8.28 (s, 1H), 7.18 (d, 2H), 6.90 (d, 2H), 4.41 (q, 2H), 3.80 (s, 3H), 1.42 (t, 3H) ppm. |
|
|